UK companies driving cell and gene therapy: Purespring case study

Purespring-logo-web.png

Purespring is revolutionising the treatment of kidney diseases with gene therapies that target a single kidney cell, the podocyte. The latest BIA's UK cell and gene therapy report explores the usage of Purespring's podocyte and the challenges and opportunities the company has had to navigate.


What does the company do? 

Purespring Therapeutics is the first gene therapy company looking at the glomerulus in the kidney, which has thus far been under-examined as a target. The company is developing two programmes at present and is also exploring other targets that will allow the pipeline to be expanded in the future. Crucially, Purespring is built as a long-term, highly integrated company that will be able to take treatments not just to the clinic, but to market. 

How will it be used?

Podocytes in the glomerulus are implicated in a large number of kidney diseases, and in many ways are ideal targets for gene therapies. They are not recycled, and do not divide, so poor function will persist throughout a patient’s life – conversely, however, this means that any gene therapy will also be persistent. Purespring’s platform has the potential for identifying and developing treatments for a large number of kidney diseases with unmet needs.

Purespring Case study.png
Prespring’s technology delivers transgenes selectively to podocytes with high efficiency.
Experiments have demonstrated that Purespring’s gene therapy expressed transgene protein (yellow) in kidney podocytes (red cytoplasm & membrane, pink nucleus) but not in other cells (blue nucleus).

What is the impact?

Initially, the focus will be on rarer monogenic nephrological conditions and the potential that exists for a fully curative treatment. Depending on the condition this can lengthen patient life, increase quality of life dramatically, or both. Other developments in kidney therapeutics recently have focused on managing symptoms, and haven’t directly targeted the disease pathway, so Purespring’s approach stands out.

What are the opportunities and challenges?

Opportunities: Purespring’s pipeline currently focuses on monogenic diseases, but their approach is not constrained to this. The ability to look at multigenic diseases, especially those beyond the rare disease space, is a major opportunity, especially when combined with Purespring’s established integrated capabilities.

Challenges: However, this is also a challenge – as an SME with fewer than 50 personnel, Purespring currently lacks the capacity to deliver all the programs that are possible with the platform. Finding further investment and expanding infrastructure will be needed before they can fully deliver on the promise.

From a technical perspective, the primary challenge in expanding to multigenic indications is to deliver treatments via the bloodstream while maintaining patient safety and avoiding off-target effects elsewhere in the body. 

Why should investors invest in this space?

In addition to the broader developments in cell and gene therapies that are common to the space, this is an excellent time for nephrology. Purespring views it as a cresting wave, with a growing understanding of the pathology of kidney diseases and potential targets driving increased interest from investors and big pharma, and in turn, this is leading to more biotechs launching in the space. The end result is more success in the past five years than in decades of previous work. 

What are the future trends for your products/processes?

With the increasing success of gene therapy projects and a growing list of approved treatments in various markets, Purespring expects an almost exponential wave of commercially available gene therapies. However, so far most of these have been for rare diseases. While seeing treatments for these conditions, many of which were entirely unmet before, is fantastic, the move into diseases of greater prevalence has the potential to impact the lives of many more patients.

 

More news and updates 

CEO Update - 20 February 2024

I'm looking forward to the BIA Committee Summit this week. It will be great to see 200 members in Westminster at one of the most lively and insightful events we do each year. I know it's the volunteer expert army that gives the BIA its unique impact with government and it's always great to understand the committee's priorities and the ideas at the intersection between committees that arise from the event.

Beyond health: why BIA is championing the biorevolution 

The BIA has named this frontier of science Deep Biotech. Our brand-new report, "Deep Biotech: Disruptive innovation for global sustainability" highlights how deep biotech is key to creating a sustainable UK bioeconomy and making the UK a science superpower that benefits all. 

Recent decision from the EPO smooths the way to obtaining patents in Europe

The BIA’s Intellectual Property Advisory Committee (IPAC) helps BIA understand and shape the environment for IP ownership to ensure strong protection for BIA member companies. Our EU policy subcommittee has taken a look at what a recent European decision means for the right to claim priority to an earlier filed patent application. This blog sets out some of the details of the case, and the practical implications for BIA members.​​​​​​​

CEO Update - 12 February 2024

It was great to see the hugely positive response we’ve had to the launch of our new report "Deep Biotech: Disruptive innovation for global sustainability". I believe we're on the cusp of a biorevolution powered by Deep Biotech, and I want our Association at the forefront of shaping the future of Deep Biotech and championing its disruptive potential.

Enter the dragon: Exploring China’s life sciences market

Next week, Chinese people across the world will be celebrating Chinese New Year. This is the “year of the dragon”, a symbol of strength for the Chinese people. It also represents prosperity, a value Chinese strive for across aspects of life, society and business.

#NAW2024: Will Smith on his Process Development Apprenticeship

I started my apprenticeship in 2020 with Gyroscope therapeutics as a process development apprentice where I worked in a small team developing a process for the production and purification of recombinant adeno-associated viruses (rAAV) to treat dry AMD.

#NAW2024: Will Crisp's journey through Level 5 Laboratory Technician Apprenticeship

I have recently finished a level 5 laboratory technician apprenticeship, while working as an apprentice at Gyroscope Therapeutics. I am 22 and started the apprenticeship after finishing my A levels.

#NAW2024: Hélène Trottin's journey through MBA apprenticeship

"The apprenticeship helped me open my mind about the extent of career possibilities in our industry and beyond. It made me more confident about my own capabilities, and how these could be of benefit to both my career and my organisation."

CEO Update - 5 February 2024

Fantastic news that new BIA Board member Ros Deegan, CEO of OMass Therapeutics has been appointed by the Prime Minister to serve on his prestigious Business Council alongside some of the biggest names from across UK business. Read on for Labour’s plan for the life sciences sector and our latest award.

#NAW2024: Role of the Institute for Apprenticeships and Technical Education

This National Apprenticeship Week (5-11 February 2024), Dr Kate Barclay, BIA's Skills Strategy Consultant, delves into the key phases of this transformation and unveils the exciting role of the Institute for Apprenticeships and Technical Education (IfATE) in working with employers to shape skills training for our future workforce. 

 

More within